Prospect: information for the user
Benferol shock 50,000 UI soft capsules
Benferol shock 100,000 UI soft capsules
colecalciferol (vitamin D3)
Read this prospect carefully before starting to take this medication, as it contains important information for you.
1. What is Benferol shock and for what it is used
2. What you need to know before starting to take Benferol shock
3. How to take Benferol shock
4. Possible adverse effects
5. Storage of Benferol shock
6. Contents of the package and additional information
This medication contains vitamin D3that regulates the absorption and metabolism of calcium, as well as the incorporation of calcium into bone tissue.
Benferol shock is used to prevent and treat vitamin D3deficiency in adults and adolescents (children ≥ 12 years of age).
Your doctor may prescribe this medication as a complement to specific medication for bone loss. Consult with your doctor or pharmacist if you have additional questions, and always follow their instructions.
Do not take Benferol shock:
If you have any of the above, consult your doctor or pharmacist before taking this medication.
Warnings and precautions
Consult your doctor or pharmacist before taking this medication:
Children
This medication is not suitable for use in children under 12 years old.
Taking Benferol shock with other medications
Inform your doctor or pharmacist that you are taking, have recently taken, or may need to take any other medication, particularly:
- Colestiramine (used to treat high cholesterol).
- Phenobarbital or barbiturates (used to treat epilepsy).
- Laxatives containing paraffin oil.
- Thiazide diuretics (to treat high blood pressure).
- Glucocorticoids (to treat inflammation).
- Cardiotonic glucosides (to treat heart conditions), e.g. digoxin.
- Actinomycin (chemotherapy)
- Imidazole (antifungal)
- Orlistat (weight loss)
Taking Benferol shock with food and drinks
See section 3 “How to take Benferol shock”.
Pregnancy, breastfeeding, and fertility
During pregnancy, daily intake of vitamin D should not exceed 600 UI.
This medication will only be used during pregnancy if a clinical deficiency of vitamin D has been diagnosed.
This medication can be used during breastfeeding. Vitamin D3passes into breast milk. This should be taken into account when administering additional vitamin D to the infant.
There are no data on the effects of vitamin D3on fertility. However, normal levels of vitamin D are not expected to have adverse effects on fertility.
If you are pregnant or breastfeeding, or think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and operating machinery
This medication has no known effects on the ability to drive or operate machinery.
Benferol shock 100,000 UI soft capsules contain Allura AC (E129) and sunset yellow FCF (E110), which may cause allergic reactions.
Benferol shock 50,000 UI soft capsules contain Allura AC (E129), which may cause allergic reactions.
If you are allergic to any of the above colorants, consult your doctor or pharmacist.
Follow exactly the administration instructions indicated by your doctor. In case of doubts, consult your doctor or pharmacist again.
The capsules should be swallowed whole with water.
This medication should be taken preferably with a full meal so that your body absorbs vitamin D3.
Adults and adolescents
The recommended dose is one capsule of 25.000 IU per month.
The dose can be adjusted according to the levels of vitamin D in the blood (25(OH)D levels) for vitamin D deficiency.
For symptomatic vitamin D deficiency treatment, the recommended dose is one capsule of 100,000 IU or two capsules of 50,000 IU in one week. A maintenance dose of 25,000 IU per month may be considered.
Use in children
This medication is not intended for use in children under 12 years old. There are other presentations of this medication that may be more suitable for children; ask your doctor or pharmacist.
If you take more Benferol shock than you should
If you have taken more of this medication than prescribed, or if a child has accidentally taken this medication, contact your doctor or emergency services to evaluate the existing risk or call the toxicology information service, phone 91 562 04 20 indicating the medication and the amount used. Bring the packaging with the medication and the medication leaflet with you to the healthcare professional.
The most frequent symptoms of overdose are: nausea, vomiting, excessive thirst, large amounts of urine produced in 24 hours, constipation, and dehydration, and high levels of calcium in the blood (hypercalcemia and hypercalciuria) detected in laboratory tests.
If you forgot to take Benferol shock
Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Benferol shock
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication may produce adverse effects, although not all people will experience them.
You should discontinue use of the medication immediately and consult with your doctor if you experience severe allergic reaction symptoms, such as:
•Swelling of the face, lips, tongue, or throat
•Difficulty swallowing
•Hives and difficulty breathing
Less Common Adverse Effects(occur in fewer than 1 in 100 people): Hypercalcemia (elevated calcium levels in the blood) and hypercalciuria (elevated calcium levels in the urine).
Rare(occur in fewer than 1 in 1,000 people): Itching, skin rash (pruritus/urticaria).
Reporting Adverse Effects
If you experienceany type of adverse effect, consult your doctor or pharmacist, even if it is apossibleadverse effect not listed in this prospectus.You can also report them directly to theSpanish System for Pharmacovigilance of Medicinal Products for Human Use:www.notificaram.es. By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging or blister after the abbreviation CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 86°F (30°C). Store in the original packaging to protect it from light.
Medications should not be disposed of through drains or in the trash.Deposit the containers and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. In this way, you will help protect the environment.
50.000 UI
- The active ingredient is colecalciferol (vitamin D3). Each soft capsule contains 1.25 mg of colecalciferol corresponding to 50,000 UI of vitamin D3.
100.000 UI
- The active ingredient is colecalciferol (vitamin D3). Each soft capsule contains 2.5 mg of colecalciferol corresponding to 100,000 UI of vitamin D3.
The other components are: all-rac-α-tocopherol (E307), medium-chain triglycerides, glycerol, gelatin, white printing ink Opacode (lacquer (E904), titanium dioxide (E171) and simethicone), red Allura AC (E129) and sunset yellow FCF (E110)(only 100,000 UI).
Appearance of Benferol shock and packaging contents
50.000 UI
Benferol shock 50,000 UI is a soft, oval-shaped, red capsule with "50" printed in white ink. It contains a slightly yellowish oily liquid.
Each box contains 1, 2, 3, or 4 capsules in blister strips.
100.000 UI
Benferol shock 100,000 UI is a soft, oval-shaped, orange capsule with "100" printed in white ink. It contains a slightly yellowish oily liquid.
Each box contains 1, 2, or 3 capsules in blister strips.
Only some packaging sizes may be commercially available.
Marketing Authorization Holder
Consilient Health Limited.
Floor 3, Block 3, Miesian Plaza,
Dublin 2, D02 Y754
Ireland
Responsible for manufacturing
Consilient Health Limited,
Block 2A Richview Office Park,
Clonskeagh, Dublin 14,
D14 Y0A5, Ireland
or
Pharma Pack Hungary Ltd.,
Vasút utca 13., Budaörs,
2040, Hungary
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
ANGELINI PHARMA ESPAÑA, S.L.
c/ Antonio Machado, 78-80
3rd floor, module A-Edificio Australia
08840 Viladecans, Barcelona (Spain)
This medicine is authorized in the member states of the European Economic Area with the following names:
Denmark: Benferol 50,000 IE bløde kapsler og Benferol 100,000 IE bløde kapsler
Finland: Benferol 50,000 IU kapselit, pehmeät och Benferol 100,000 IU kapselit, pehmeät
Norway: Benferol 50,000 IU myke kapsler og Benferol 100,000 IU myke kapsler
Sweden: Benferol 50,000 IU mjuka kapslar och Benferol 100,000 IU mjuka kapslar
Spain: Benferol choque 50,000 UI cápsulas blandas y Benferol choque 100,000 UI cápsulas blandas
Last review date of this leaflet:January 2024.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.